Search clinical trials for: Conventional T-cells

Total 15736 results

Xcyte Therapies

Completed

Autologous T Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL) Patients

Chronic Lymphocytic Leukemia

United States
Mario Arpinati
European Commission

Recruiting

Multiple Donor Treg DLI for Severe Refractory Chronic GVHD (TREG2015001)

Chronic Graft Versus Host Disease

Italy
Chimeric Therapeutics

Recruiting

CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma

Glioblastoma Multiforme of Brain

United States
Great Ormond Street Hospital for Children NHS Foundation...
Medical Research Council; UCL Great Ormond Street Institute of Child Health

Recruiting

Base Edited CAR7 T Cells to Treat T Cell Malignancies (TvT CAR7) (TvT CAR7)

Relapsed/Refractory T-cell Acute Lymphoid Leukaemia

United Kingdom
Poseida Therapeutics, Inc.

Recruiting

P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors

Renal Cell Carcinoma | Breast Cancer | Nasopharyngeal Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma

United States
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome

Autoimmune Diseases | Sjogren's Syndrome

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus

Autoimmune Diseases | Systemic Lupus Erythematosus

China
Mahmoud Ramadan mohamed Elkazzaz

Not yet recruiting

CRISPR/Cas9-modified Human T Cell ( PD-1and ACE2 Knockout Engineered T Cells ) for Inducing Long-term Immunity in COVID-19 Patients

COVID-19 Respiratory Infection
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL

B-Cell Acute Lymphoblastic Leukemia, Adult

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Lymphoma, B-Cell | Leukemia, B-cell

China
Shenzhen Geno-Immune Medical Institute
Shenzhen Children's Hospital

Recruiting

4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma

Neuroblastoma

China
University College, London

Active, not recruiting

Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma (CAROUSEL)

Primary CNS Lymphoma

United Kingdom
Fuda Cancer Hospital, Guangzhou

Withdrawn

Chimeric Antigen Receptor-Modified T Cells for Breast Cancer

Breast Cancer

China
M.D. Anderson Cancer Center
Miltenyi Biotec B.V. & Co. KG

Completed

Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation

Lymphoma | Leukemia

United States
University of Zurich

Completed

Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma

Switzerland
The Netherlands Cancer Institute

Unknown

Study With T-cel Receptor Gene Therapy in Metastatic Melanoma (TCR)

Stage IV Skin Melanoma | Eye; Melanoma

Netherlands
Nanjing Medical University

Unknown

Safety and Efficacy Study of Regulatory T Cells in Treating Autoimmune Hepatitis (Treg)

Autoimmune Diseases
Second Affiliated Hospital, School of Medicine,...
TCRx Therapeutics Co.Ltd

Not yet recruiting

TCRx_T Cells for Advanced or Recurrent Gastric/Gastroesophageal Junction Cancer After Failure of First Chemotherapy

Gastric Cancer | Gastroesophageal-junction Cancer
Celyad Oncology SA

Terminated

Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer (LINK)

Colon Cancer Liver Metastasis

Belgium
Celyad Oncology SA

Unknown

Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases (SHRINK)

Colon Cancer Liver Metastasis

Belgium
Shenzhen Geno-Immune Medical Institute

Recruiting

NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL

T-Cell Acute Lymphoblastic Leukemia

China
Ever Supreme Bio Technology Co., Ltd.

Not yet recruiting

A Safety And Efficacy Study Of Allogeneic CAR Gamma-Delta T Cells in Subjects With Relapsed/Refractory Solid Tumors (CAR001)

Solid Tumor

Taiwan
Great Ormond Street Hospital for Children NHS Foundation...
Wellcome Trust

Recruiting

Base Edited CAR T Cells Against AML: Deep Conditioning Ahead of Allogeneic Stem Cell Transplantation (CARAML)

Relapsed Acute Myeloid Leukaemia

United Kingdom
RenJi Hospital
Gracell Biotechnology Shanghai Co., Ltd.

Recruiting

Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients

CAR-T Cell Therapy

China
Zhejiang University
Gracell Biotechnology Shanghai Co., Ltd.

Recruiting

Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus Erythematosus

CAR-T

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune Nephritis

Autoimmune Diseases | Lupus Nephritis | Immune Nephritis

China
Precision BioSciences, Inc.

Recruiting

Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies

Hematologic Malignancy | CD19 Expressing Malignancies

United States
Shenzhen Geno-Immune Medical Institute

Recruiting

Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies

Acute Myeloid Leukemia | T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | NK Cell Lymphoma

China
Sorrento Therapeutics, Inc.

Completed

Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients

Relapsed or Refractory Multiple Myeloma

United States
Xcyte Therapies

Unknown

T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant

Multiple Myeloma

United States
Children's National Research Institute

Recruiting

Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors

Solid Tumor

United States
Everett Meyer
National Cancer Institute (NCI)

Withdrawn

Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant

Graft Versus Host Disease

United States
AGC Biologics S.p.A.
Horizon 2020 - European Commission

Terminated

Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma

Acute Myeloid Leukemia | Multiple Myeloma

Italy, Czechia
Baylor College of Medicine
National Cancer Institute (NCI); Stand Up To Cancer; Center for Cell and Gene... and other collaborators

Recruiting

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

Sarcoma | Soft Tissue Sarcoma | Osteosarcoma | Ewing Sarcoma | Rhabdomyosarcoma | Synovial Sarcoma | HER-2 Protein Overexpression | Undifferentiated Sarcoma

United States
Fudan University
Guangzhou Bioresette Biomedical Technology Co., Ltd.; Chaosu Hu，Principal Investigator...

Recruiting

Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Sheba Medical Center

Unknown

T-Cell Vaccination in Multiple Sclerosis (MS)

Multiple Sclerosis

Israel
Sheba Medical Center

Unknown

TCV -01-002: T-Cell Vaccination in the Treatment of Probable Multiple Sclerosis

Multiple Sclerosis

Israel
Radboud University Medical Center

Terminated

T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation

Lymphoma | Leukemia, Myeloid | Myelodysplastic Syndrome | Leukemia, Lymphocytic | Leukemia, Myeloid, Chronic

Netherlands
Cerus Corporation

Completed

A Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S303 Treated Red Blood Cells (S303 RBC)

Focus: Assess Post Infusion Viability of S303 RBCs

United States
Shenzhen BinDeBio Ltd.
Henan Provincial People's Hospital

Recruiting

Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies

Glioma | Gastric Cancer | Hepatoma | Esophagus Cancer

China
Wake Forest University Health Sciences

Terminated

T-cell Depleted Alternative Donor Transplantation

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Immune Deficiency | Lymphomas | Bone Marrow Failure | Osteopetrosis | Hemoglobinopathy

United States
Third Military Medical University

Unknown

CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma

Burkitt Lymphoma | Acute Lymphoblastic Leukemia
Ciusss de L'Est de l'Île de Montréal

Recruiting

Donor-Derived EBV-Specific T Cells for Life Threatening EBV-lymphoma (OLIP-EBV-TCL-01-HMR01)

EBV Associated Lymphoma

Canada
Shanghai Cell Therapy Group Co.,Ltd

Recruiting

An Exploratory Study by Fast CAR T Cells

Solid Tumor

China
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma

Lymphoma, Non-Hodgkin | Diffuse Large B Cell Lymphoma

China
Shenzhen Geno-Immune Medical Institute
The Second Affiliated Hospital of Hainan Medical University; Beijing Jingdu...

Recruiting

4SCAR19U T Cells Targeting B Cell Malignancies

B Cell Malignancies

China
Shenzhen Geno-Immune Medical Institute
The Second Affiliated Hospital of Hainan Medical University; Beijing Jingdu...

Recruiting

Universal 4SCAR7U Targeting CD7-positive Malignancies

Acute Myeloid Leukemia | T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | NK Cell Lymphoma

China
Shanghai Changzheng Hospital
CARsgen Therapeutics Co., Ltd.

Recruiting

Study of CT071 Injection in RRMM or PPCL

Multiple Myeloma | Primary Plasma Cell Leukemia

China
CARsgen Therapeutics Co., Ltd.
Xiangya Hospital of Central South University; Peking University People's Hospital and other collaborators

Active, not recruiting

Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)

Multiple Myeloma

China
The Pregene (ShenZhen) Biotechnology Company, Ltd.
Henan Cancer Hospital

Unknown

BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma (BCMA CAR-T)

Relapsed and Refractory Multiple Myeloma

China

Search clinical trials for: Conventional T-cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations